The International Neoadjuvant Melanoma Consortium (INMC) has published an updated pooled analysis of five-year survival outcomes with neoadjuvant therapy in melanoma in Nature.

The analysis pools long-term follow-up data across consortium trials of neoadjuvant treatment strategies for melanoma, extending previously reported results with a five-year survival endpoint. The INMC, a multi-institutional research collaboration, has been central to establishing neoadjuvant immunotherapy as a meaningful therapeutic stage in the management of resectable melanoma, and the new pooled dataset represents the consortium's most mature survival analysis to date.

Neoadjuvant therapy — systemic treatment delivered before surgical resection of the primary tumor and regional nodes — has gained considerable momentum in melanoma over the past several years. Earlier INMC pooled analyses demonstrated that pathologic response to neoadjuvant immune checkpoint inhibition correlates strongly with survival outcomes, with patients achieving a major or complete pathologic response showing markedly better recurrence-free and overall survival than non-responders. The updated analysis now anchors those findings to the five-year mark, a benchmark that matters for counseling patients with stage III disease about expected long-term benefit.

The full study, including the exact cohorts, treatment regimens, and survival estimates, is available in Nature. Dermatologists and oncology teams managing cutaneous melanoma will want to review the primary publication for the specific effect sizes, as the pooled dataset aggregates patients across multiple trial designs and regimens within the consortium.

For the dermatology community, the report reinforces a practice-relevant shift: neoadjuvant therapy is no longer an investigational concept confined to academic centers. Pathologic response assessment at surgery has become a decision point that shapes adjuvant treatment and surveillance intensity, and dermatologists involved in the co-management of melanoma patients increasingly encounter patients who have received systemic therapy before wide local excision and lymph node dissection.

The updated INMC analysis arrives as treatment sequencing in resectable melanoma continues to evolve rapidly. Its five-year survival data will help refine which patients benefit most from neoadjuvant strategies and how long that benefit persists, and future consortium work is expected to build on these results to further optimize patient selection and treatment duration.